TrialInternational journal of rheumatic diseases2017

Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.

Thomas Stock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.